Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

Soon Kyu Lee; Pil Soo Sung; Sung Soo Park; Chang Ki Min; Heechul Nam; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon

doi:10.1093/cid/ciab302

Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

Soon Kyu Lee, Pil Soo Sung, Sung Soo Park, Chang Ki Min, Heechul Nam, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.

Original language	English
Pages (from-to)	E1372-E1375
Journal	Clinical Infectious Diseases
Volume	73
Issue number	6
DOIs	https://doi.org/10.1093/cid/ciab302
State	Published - 15 Sep 2021

Bibliographical note

Funding Information:
This research was supported by the Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea (P. S. S.). This study was also supported by The Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation (S. K. L.).

Publisher Copyright:
© The Author(s) 2021.

Keywords

Daratumumab
hepatitis B virus
multiple myeloma
reactivation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciab302

Cite this

@article{6a177dcf0b8e4da68d7d91f4fcba421e,

title = "Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma",

abstract = "The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.",

keywords = "Daratumumab, hepatitis B virus, multiple myeloma, reactivation",

author = "Lee, {Soon Kyu} and Sung, {Pil Soo} and Park, {Sung Soo} and Min, {Chang Ki} and Heechul Nam and Jang, {Jeong Won} and Choi, {Jong Young} and Yoon, {Seung Kew}",

note = "Funding Information: This research was supported by the Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea (P. S. S.). This study was also supported by The Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation (S. K. L.). Publisher Copyright: {\textcopyright} The Author(s) 2021.",

year = "2021",

month = sep,

day = "15",

doi = "10.1093/cid/ciab302",

language = "English",

volume = "73",

pages = "E1372--E1375",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

AU - Lee, Soon Kyu

AU - Sung, Pil Soo

AU - Park, Sung Soo

AU - Min, Chang Ki

AU - Nam, Heechul

AU - Jang, Jeong Won

AU - Choi, Jong Young

AU - Yoon, Seung Kew

N1 - Funding Information: This research was supported by the Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea (P. S. S.). This study was also supported by The Research Supporting Program of The Korean Association for the Study of the Liver and The Korean Liver Foundation (S. K. L.). Publisher Copyright: © The Author(s) 2021.

PY - 2021/9/15

Y1 - 2021/9/15

N2 - The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.

AB - The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.

KW - Daratumumab

KW - hepatitis B virus

KW - multiple myeloma

KW - reactivation

UR - http://www.scopus.com/inward/record.url?scp=85116958501&partnerID=8YFLogxK

U2 - 10.1093/cid/ciab302

DO - 10.1093/cid/ciab302

M3 - Article

C2 - 33846712

AN - SCOPUS:85116958501

SN - 1058-4838

VL - 73

SP - E1372-E1375

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this